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The mechanism by which the epidermal growth
factor receptor (EGFR) is activated upon dimer-
ization has eluded definition. We find that the
EGFR kinase domain can be activated by in-
creasing its local concentration or by mutating
a leucine (L834R) in the activation loop, the
phosphorylation of which is not required for ac-
tivation. This suggests that the kinase domain is
intrinsically autoinhibited, and an intermolecu-
lar interaction promotes its activation. Using
further mutational analysis and crystallography
we demonstrate that the autoinhibited confor-
mation of the EGFR kinase domain resembles
that of Src and cyclin-dependent kinases
(CDKs). EGFR activation results from the forma-
tion of an asymmetric dimer in which the C-ter-
minal lobe of one kinase domain plays a role
analogous to that of cyclin in activated CDK/cy-
clin complexes. The CDK/cyclin-like complex
formed by two kinase domains thus explains
the activation of EGFR-family receptors by
homo- or heterodimerization.
INTRODUCTION
Members of the epidermal growth factor receptor family
(EGFR/ErbB1/HER1, ErbB2/HER2, ErbB3/HER3, and
ErbB4/HER4) are transmembrane tyrosine kinases that
are activated by ligand-induced dimerization (Figure 1A)
(Schreiber et al., 1983; Ushiro andCohen, 1980). These re-
ceptors play critical roles in regulating cell proliferation,
differentiation, and migration, and their abnormal activa-
tion is associated with a variety of human cancers (Yarden
and Sliwkowski, 2001).The structural basis for ligand-induced dimerization of
the extracellular region of EGFR family members is now
well understood (Cho and Leahy, 2002; Ferguson et al.,
2003; Garrett et al., 2002; Ogiso et al., 2002; Schlessinger,
2002). Dimerization results in the phosphorylation of tyro-
sine residues in the C-terminal tail segments, which serve
as docking sites for signaling molecules that contain SH2
or PTB domains and are responsible for onward transmis-
sion of the signal (Yarden and Sliwkowski, 2001). EGFR,
ErbB2, and ErbB4 contain catalytically competent kinase
domains and can form heterodimeric pairs with each
other. ErbB3 contains an inactive kinase domain, but it
can pair with and activate the other members of the family
(Yarden and Sliwkowski, 2001).
The kinase activity of EGFR is stimulated by ligand en-
gagement in a manner that depends on intermolecular
interactions (Yarden and Schlessinger, 1987). The purified
intracellular region of EGFR is activated by aggregation in-
duced by a variety of agents (Mohammadi et al., 1993;
Wedegaertner and Gill, 1989). This activation is not simply
due to trans-phosphorylation of the activation loop be-
cause, in contrast to most kinases, phosphorylation of
the EGFR activation loop is not critical to its activation
(Burke and Stern, 1998; Gotoh et al., 1992; Moriki et al.,
2001; Stamos et al., 2002).
Crystal structures of the EGFR kinase domain have
been determined previously in two distinct crystal lattices.
In one (crystal form A) the kinase domain is unphosphory-
lated but adopts an active conformation, either in a ligand-
free form or in complex with the cancer drug Erlotinib
(Tarceva) (Stamos et al., 2002). The EGFR kinase domain
in a second crystal form (crystal form B;Wood et al., 2004)
is bound to the drug Lapatinib (Tykerb) and is in an inactive
conformation that resembles closely that of inactive Src-
family kinases (Schindler et al., 1999; Xu et al., 1999) and
cyclin-dependent kinases (CDKs) (De Bondt et al., 1993).
An activating heterozygous mutation in the activation
loop of the kinase domain of EGFR, L834R (also identified
as Leu858 in an alternative numbering of the human EGFRCell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc. 1137
Figure 1. Ligand-Induced Dimerization
of EGFR and Active and Inactive States
of Its Kinase Domain
(A) General view of the ligand-induced dimer-
ization and activation process of EGFR. The ki-
nase domain is activated through a previously
unknown mechanism.
(B) Detailed view of the catalytic site of the
EGFR kinase domain in the active conforma-
tion. Leu834 and L837 are surface exposed
and the Lys721/Glu738 ion pair is intact in
this conformation.
(C) Detailed view of the catalytic site in the inac-
tive conformation. Leu834 and L837 pack
against helix aC, preventing the formation of
the Lys721/Glu738 ion pair. The right panel
shows the electron density around residues
834–838 for the V924R kinase domain mutant,
at 3s from a simulated annealing omit map with
coefficients (jFoj  jFcj)eiac, where the calcu-
lated structure factors are generated from
a model that does not contain these residues.
The structures shown in (B) and (C) were deter-
mined in the absence of drugmolecules as part
of this work and are similar to structures deter-
mined previously in complex with the drugs
Erlotinib and Lapatinib, respectively (Stamos
et al., 2002; Wood et al., 2004).sequence), has been found frequently in lung cancer pa-
tients (accounting for 41% of EGFR mutations in these
cancers) (Jiang et al., 2005; Lynch et al., 2004; Paez
et al., 2004; Pao et al., 2004; Shigematsu and Gazdar,
2006; Sordella et al., 2004). An adjacent leucine residue
(Leu837) is mutated to glutamine in some lung cancer pa-
tients (Shigematsu et al., 2005). These residues are either
partially (Leu834) or completely (Leu837) surface exposed
and do not play an obvious structural role in the active
conformation (Figure 1B). In contrast, the importance of
these two residues is obvious upon consideration of the
Src/CDK-like inactive conformation because both resi-
dues pack against hydrophobic sidechains in the interior
of the kinase domain while buttressing a displaced orien-
tation of a catalytically critical helix in the N-lobe, helix aC
(Figure 1C). Replacement of either leucine by a polar side-
chain is likely to destabilize the Src-like inactive conforma-
tion and thereby activate the kinase domain. Interestingly,
Erlotinib is incompatible with the Src/CDK-like inactive
conformation, which may explain why activating muta-
tions potentiate the effectiveness of the closely related
drug Gefitinib (Lynch et al., 2004; Paez et al., 2004).
In this paper we show that the isolated kinase domain
of EGFR has low basal activity, and that its activity is in-1138 Cell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc.creased substantially upon replacing Leu834 by arginine.
This demonstrates that the wild-type kinase domain on its
own is indeed in an autoinhibited state, and we wondered
why the original crystal structure of the EGFR kinase do-
main (Stamos et al., 2002) as well as two new structures
we have determined (see below) are in the active confor-
mation. One possibility is that the high protein concentra-
tions used in crystallization (200 mM) might mimic the
high local concentration of kinase domains that is induced
by receptor dimerization, leading to the formation of an
activated dimer in the crystal lattice. The only available in-
active structure of the EGFR kinase domain (crystal form
B) is likely to be trapped by the bound kinase inhibitor
Lapatinib, which is incompatible with the active structure
seen in crystal form A.
Examination of the crystal lattice of the active form of
the kinase domain reveals two potentially important crys-
tallographic dimers. One is symmetric, with two kinase
domains interacting in a head-to-tail fashion though a
primarily electrostatic interface, as discussed before
(Landau et al., 2004). The second one is an asymmetric
dimer in which one kinase domain interacts with another
in a manner analogous to that of a cyclin with an activated
cyclin-dependent kinase (Jeffrey et al., 1995). We present
Figure 2. Catalytic Activity of the Wild-Type EGFR Kinase Domain and Various Mutants in Solution and Attached to Lipid Vesicles
(A) Catalytic efficiency (kcat/KM) of thewild-type andmutants of the EGFR kinase domain in solution (yellow) and linked to vesicles (blue). Fold-increase
of thecatalytic efficiencyuponattachment to vesicles for eachprotein is indicated on topof thebluebars.WT:wild-type kinase domain (residues 672 to
998).WT_no_His: thewild-typeEGFRkinasedomainwith the (His)6 tag removed. All other proteins in this graph havean intact (His)6 tag.DOGS-NTA-Ni
content of vesicles is 5 mole percent in these experiments. Error bars represent standard errors of the linear fittings (see Experimental Procedures).
(B) Concentration-dependent activation of thewild-type kinase domain upon attachment to lipid vesicles. The specific activities of thewild-type EGFR
kinase domain in solution andwith vesicles containing variousmole percentages of DOGS-NTA-Ni are shown. The overall concentration of the protein
and DOGS-NTA-Ni lipids in the bulk solution are kept fixed at 3.5 mM and 12.5 mM, respectively, for all measurements. Data shown are the means +
range of variation from two independent experiments.amutational analysis that demonstrates the importance of
the CDK/cyclin-like dimer for the activation of the EGFR
kinase domain. We also show that the symmetric electro-
static dimer seen in crystal form A (Landau et al., 2004) is
unlikely to be relevant for EGFR activation. One compel-
ling aspect of the CDK/cyclin-like model is its ability to ex-
plain the interactions of the catalytically dead ErbB3 re-
ceptor with other EGFR family members, which we have
tested by cotransfecting mammalian cells with active
and inactive forms of EGFR. In addition, we have crystal-
lized an EGFR kinase domain variant bearing a mutation
(V924R) at the CDK/cyclin-like interface. Strikingly, the
mutant EGFR kinase domain crystallizes in a new crystal
lattice and adopts an inactive Src/CDK-like conformation.
RESULTS AND DISCUSSION
The EGFR Kinase Domain Is Autoinhibited and Can
Be Activated in a Concentration-Dependent Manner
when Localized to Vesicle Surfaces
We expressed and purified the L834R mutant form of the
kinase domain (residues 672–998 with an N-terminal His-
tag) and measured its kinase activity toward a peptide
substrate. The value of the catalytic efficiency (kcat/KM)
for the L834R mutant is 20-fold higher than that for the
wild-type kinase domain, indicating that the wild-type
kinase domain is autoinhibited (Figure 2A).
The EGFR kinase domain is monomeric in solution at
concentrations up to 50 mM (Figure S1). The local concen-
tration of kinase domains in a dimeric receptor is esti-mated to be in the millimolar range. In order to increase
the local concentration in a controlled fashion we added
a hexa-histidine tag to the kinase domain and localized it
to the surface of small unilamellar vesicles containing
lipids with a nickel-nitrilotriacetate head group (1, 2-Dio-
leoyl-sn-Glycero-3-{[N(5-Amino-1-Carboxypentyl)iminodi-
Acetic Acid]Succinyl} Nickel salt, DOGS-NTA-Ni) (Dorn
et al., 1998). The density of the kinase domain on individ-
ual vesicles was controlled by varying the mole ratio of the
DOGS-NTA-Ni lipids and the 1,2-Dioleoyl-sn-Glycero-3-
Phosphocholine (DOPC) lipids that constitute the vesicles.
A similar method has been used to study the activation of
the CheA histidine kinase by the aspartate receptor from
E. coli (Shrout et al., 2003).
The density of DOGS-NTA-Ni lipids in the vesicles is
varied from 0.5 to 5.0 mole percent. The dissociation con-
stant for attachment of the His-tagged kinase domain to
the vesicle is estimated to be2 mMand the total concen-
tration of DOGS-NTA-Ni lipid is maintained at 12.5 mM in
these experiments to ensure localization of the His-tagged
protein to the vesicles. The effective local concentration of
kinase domains is approximately in the range of 0.4 mM
(for 100 nm vesicles containing 0.5 mole % DOGS-NTA-
Ni) to4mM (for 5 mole%DOGS-NTA-Ni) (see Table S1).
The wild-type kinase domain attached to vesicles dis-
plays a significantly increased catalytic activity relative
to that of the kinase domain in solution (up to 15-fold in-
crease in the value of kcat/KM) (Figure 2). The specific ac-
tivity increases when the density of the kinase molecules
on individual vesicles is increased, while keeping theCell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc. 1139
Figure 3. Crystal Structures of the EGFR Kinase Domain in the Active and Inactive Conformations
(A) Crystal structure of the EGFR kinase domain in complex with the ATP analog substrate peptide conjugate. The kinase adopts an active con-
formation. Electron density (calculated in the same way as in Figure 1C) for the ATP moiety of the ATP analog-peptide conjugate and seven residues
in the C-terminal tail segment is shown in yellow.
(B) Crystal structure of the V924R mutant of the EGFR kinase domain in complex with AMP-PNP. The kinase adopts a Src/CDK-like inactive confor-
mation. The approximate location of the V924R mutation is indicated.
(C) Crystal structure of an inactive Src kinase in complex with AMP-PNP (PDB ID: 2SRC).overall concentrations of the His-tagged kinase domain
and DOGS-NTA-Ni constant (Figure 2B). This suggests
that an intermolecular interaction is involved in the activa-
tion of the kinase domain.
Vesicles containing no DOGS-NTA-Ni lipids do not stim-
ulate the level of kinase activity (Figure 2B). Conversely, re-
moval of theHis-tagbyproteolytic cleavagedoes not result
in an increase in catalytic activity in the presence of the
DOGS-NTA-Ni-containing vesicles; the basal activity in so-
lution isunchangedby theproteolytic treatment (Figure2A).
These experiments rule out the possibility that the activa-
tion of the vesicle-linked kinase domain is due to nonspe-
cific interactions between the lipids and the protein.
One simple explanation for the concentration depen-
dence of the activation of the vesicle-linked kinase domain
is that it is a consequence of increased trans-phosphory-
lation of the kinase domain on Tyr845 in the activation
loop, which corresponds to the site of activating phos-
phorylation in many kinases (Huse and Kuriyan, 2002).
This is ruled out by experiments on a mutant form of the
EGFR kinase domain with this tyrosine residue replaced
by phenylalanine (Y845F). Y845F is activated upon attach-
ment to vesicles to a similar extent as the wild-type EGFR
kinase domain (Figure 2A).
New Crystal Structures of the EGFR Kinase Domain
in an Active Conformation
We screened extensively for conditions that yield crystals
of the wild-type EGFR kinase domain but succeeded only1140 Cell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc.in obtaining crystals with the same lattice as described
previously (Stamos et al., 2002), although under very dif-
ferent conditions. We obtained crystals of the apo-EGFR
kinase domain in 25% PEG4K, 6% isopropanol, 100 mM
HEPES, pH 7.5. Two different ATP analog-peptide conju-
gates were used for crystallization with the EGFR kinase
domain. In one the peptide segment corresponds to 12
residues spanning Tyr1173 in the C-terminal tail of
EGFR, but cocrystallization trials yielded crystals in 1 M
NaMalonate, 100 mM HEPES, pH 7.0 that do not appear
to contain the substrate analog. Crystals of the kinase do-
main in complex with another ATP analog-peptide conju-
gate (corresponding to a c-Src substrate; Levinson et al.,
2006) were grown in 18% PEG3350, 0.2 M LiCitrate, 100
mM HEPES, pH 7.5. The unit cell parameters for these
crystals are very similar to those for the original form A
crystals, which were obtained under different conditions
(1 M Na/K tartrate, 100 mM MES, pH 7.0) (Stamos et al.,
2002).
The structure of the kinase domain complexed with the
ATP analog-peptide conjugate (Figures 1B and 3A) shows
that all the catalytic residues are positioned appropriately
for catalysis, as judged by comparison with the structures
of insulin receptor kinase-substrate complexes (Parang
et al., 2001). Given the persistent formation of crystal
form A under a wide variety of crystallization conditions,
we wondered whether an intrinsic tendency of the kinase
domain to dimerize at high concentrations may promote
the formation of a specific crystal lattice that stabilizes
Figure 4. The Asymmetric CDK/Cyclin-like Crystallographic Dimer of the EGFR Kinase Domain
(A) Overview of the asymmetric dimer, and comparison with the structure of the CDK2/cyclinA complex (PDB ID: 1HCL).
(B) Detailed view of the asymmetric dimer interface. Monomer A (the activated kinase) is shown in surface representation in the first exploded view.
Hydrophobic interfacial residues frommonomer B are highlighted. In the second exploded viewmonomer B (the cyclin-like kinase) is shown in surface
representation, and hydrophobic interfacial residues from monomer A are highlighted.the active conformation. Previous analysis of crystal form
A had focused attention on a symmetric crystallographic
dimer held together primarily by electrostatic interactions
(Landau et al., 2004). Crystal form A also contains an ex-
tensive hydrophobic interface between two kinase do-
mains that results from a 3-fold screw rotation (Figures
4A and 4B) (i.e., one kinase domain in a pair is rotated
by 120º about an axis relative to the other one and is
also translated along that axis by 42 A˚; see Figure S3A
for the precise transformation). This asymmetric dimer
juxtaposes the C-lobe of one kinase domain (monomer
B) against the N-lobe (with extensive interactions span-ning helix aC) of the other kinase domain (monomer A)
(Figures 4A and 4B).
A striking aspect of the asymmetric interaction between
the two EGFR kinase domains in the second dimer is its
resemblance to the interaction between activated CDK2
and cyclinA (Figure 4A), with the C-lobe of monomer B in
the EGFR kinase dimer taking a position relative to mono-
mer A that is analogous to that of cyclinA in the active
CDK/cyclin complex (Jeffrey et al., 1995). Although the
structure of the C-lobe of the kinase domain is unrelated
to that of the cyclins, key elements of the interaction, par-
ticularly the engagement of helix aC of monomer A, areCell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc. 1141
Figure 5. The Symmetric Electrostatic Dimer Is Not Important for EGFR Activation
(A) Residues involved in the symmetric dimer interface. The twomonomers are moved away and rotated relative to each other as indicated to provide
a clearer view of residues involved in the dimer interface. Blue: residues in the C-terminal tail segment (Glu991 and Tyr992); Cyan: residue in the N-
lobe of the kinase (Lys828); Red: residues in the C-lobe of the kinase (Lys799, Arg938, Ile942, and Lys946).
(B) Mutations of interfacial residues in the C-lobe of the kinases, except K799E, do not affect receptor phosphorylation. The anomalous behavior of
K799E is not understood (see Supplemental Data).similar in general terms. An insightful earlier study had pro-
posed several potential models for dimerization of the
EGFR kinase domain in the absence of direct structural in-
formation and had speculated that the base of the C-lobe
of the kinase domain might engage helix aC of another ki-
nase domain through hydrophobic interactions (Groenen
et al., 1997).
The Symmetric Dimer Seen in the Crystals of the
Active Kinase Domain Does Not Play a Significant
Role in the Activation of EGFR
We havemeasured the effect on EGFR activation of muta-
tions at the symmetric dimer interface (Figure 5A) by using
a cell transfection assay in which the levels of phosphory-
lation at three sites in the C-terminal tail of the full-length
receptor (Tyr1045, Tyr1068, and Tyr1173) are monitored.
Four of these mutant receptors (I942E, K946E, R938E,
and a doublemutant R938/I942E) show a robust response
to EGF stimulation (Figure 5B). Given the central location
of these residues within the symmetric dimer interface,
these results argue against the importance of this dimer
in the activation process (see Supplemental Data for
more information).
Further evidence that the symmetric dimer is not in-
volved in the activation process is provided by the vesi-
cle-linked assay for the activity of the kinase domain.
The C-terminal tail segment is a central element of the
symmetric dimer, but a variant of the kinase domain in
which the majority of the C-terminal tail segment is re-
moved (containing a deletion spanning residues 965–
998) is activated upon attachment to vesicles to a much
higher level than seen for the kinase domain with the intact
C-terminal fragment (Figure 2A). These results indicate1142 Cell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc.that the C-terminal tail segment suppresses the catalytic
activity of EGFR kinase domain, consistent with previous
studies (Chang et al., 1995; Wood et al., 2004), but is not
required for the activation mechanism.
An Allosteric Activation Mechanism Suggested by
the Asymmetric EGFR Kinase Domain Dimer
The CDK/cyclin-like dimer interface is formed by the N-
terminal extension (residues 672–685), the C helix, and
the loop between strands b4 and b5 ofmonomer A (the ac-
tivated kinase domain) and the loop between helices aG
and aH, helix aH, and the end of helix aI from monomer
B (the cyclin-like kinase domain), burying2019 A˚2 of sur-
face area between them (Figure 4). As in the CDK2/cyclinA
interface (Jeffrey et al., 1995), the core of the asymmetric
EGFR kinase domain dimer is dominated by hydrophobic
interactions, involving primarily residues Leu680, Ile682,
Leu736, Leu758, and Val762 from monomer A (in the N-
lobe of the activated kinase) and Ile917, Tyr920, Met921,
Val924, and Met928 from monomer B (in the C-lobe of
the cyclin-like molecule) (Figure 4B). Several hydrogen
bonds are also present at the periphery of the interface.
Many features of the Src/CDK-like inactive conforma-
tion are incompatible with formation of the CDK/cyclin-
like interface. For example, the N-terminal extension
adopts an extended conformation in the active structure
and forms part of the CDK/cyclin-like dimer interface
(Figure 4B). This forces the removal of the side chain of
Leu680 out of a hydrophobic pocket that is formed be-
tween helix aC and strand b5 in the inactive structure
(Wood et al., 2004) and into the heart of the CDK/cyclin-
like interface (Figure 4B). The residue corresponding to
Leu680 in c-Src, Hck, and Abl is a tryptophan residue
(Trp260 in c-Src) that acts as a wedge between helix aC
and the main body of the kinase domain in the Src/CDK-
like inactive conformation, preventing activation (Levinson
et al., 2006; Xu et al., 1999).
The 3-fold screw axis that generates the asymmetric
CDK/cyclin-like dimer positions the two kinase domains
such that their N-terminal residues are 50 A˚ apart and
can both be connected, in principle, to the juxtamembrane
and transmembrane segments presented at the mem-
brane surface (Figure 4). The precise disposition of the
C-terminal ends of the extracellular domains in an acti-
vated EGFR dimer is unknown, but they are estimated to
be 20 A˚ apart (Burgess et al., 2003). This gap between
the ends of the dimeric extracellular region and the asym-
metric CDK/cyclin-like dimer could be compensated for
by residues 615–671 of the receptors, which are between
the two regions and are not present in the crystal struc-
tures. If the juxtamembrane segment retains a degree of
flexibility, then it is possible that the two kinase domains
in the dimer can switch positions dynamically and activate
each other. The juxtamembrane and transmembrane
segments may have other important regulatory roles
(McLaughlin et al., 2005) and may prevent activation of
the kinase domain when ligand-independent dimers are
formed (Moriki et al., 2001).
The generation of an open-ended higher-order oligo-
mer of kinase domains along the 3-fold screw axis ap-
pears unlikely within the context of the full-length recep-
tor at the cellular membrane because a third kinase
domain would have its N-terminal segment pointing
away from the plane of the membrane (Figure S3A). We
conclude therefore that activation of EGFR involves the
formation of a CDK/cyclin-like dimer of kinase domains,
as illustrated in Figure 4.
A sequence alignment of EGFR family members shows
that the residues involved in the N- or the C-lobe faces of
the CDK/cyclin-like interaction are essentially invariant in
the three catalytically active EGFR family members
(EGFR, HER2, and HER4) (Figure 7A), strongly suggesting
that HER2 and HER4 are autoinhibited and activated by
the same mechanism (Figure 7B). The sequence compar-
isons show that residues in ErbB3 that correspond to the
C-lobe face of the interface (i.e., the cyclin-like face) are
very similar to the residues found in other members in
the family. In contrast, residues in ErbB3 that correspond
to the N-lobe face (i.e., on the kinase domain that is being
activated) are divergent (Figure 7A). This suggests that the
catalytically inactive ErbB3 molecule functions essentially
as a cyclin-like activator for other EGFR family members.
ErbB3 itself does not need to be activated, and we pre-
sume that there has been no selective pressure for main-
taining residues at the N-lobe face of ErbB3.
Crystal Structure of the V924R Mutant of the EGFR
Kinase Domain Reveals a Src/CDK-like Inactive
Conformation
The Src/CDK-like inactive conformation of the EGFR ki-
nase domain has only been observed in a complex withthe drug Lapatinib (Wood et al., 2004), leaving open the
possibility that this particular conformation is induced by
the drug. We introduced a mutation (V924R) in the EGFR
kinase domain, located in the center of the C-lobe face
of the CDK/cyclin-like dimer interface, and crystallized
the mutant protein in the presence of the ATP analog
AMP-PNP and determined its structure at 2.6 A˚ resolution
(Table S3).
The mutant EGFR kinase domain crystallizes in a new
crystal form, with two molecules in the asymmetric unit.
The structures of the two monomers are essentially iden-
tical and are very similar to that of the previously deter-
mined Lapatinib complex (Figure S4B). Strong electron
density is present for the N-terminal base of the activation
loop, which forms a helical turn, stabilizing the outwardly
displaced helix aC (Figures 1C and 3B). Our structure
also permits visualization of the loop leading into helix
aC (Figures 1C and 3B), which is disordered in the Lapati-
nib complex. This loop makes close interactions with the
inactive helical conformation of the N-terminal base of
the activation loop, explaining the activating effect of an-
other set of lung cancer mutations in EGFR, in which this
loop is deleted (Lynch et al., 2004; Paez et al., 2004;
Shigematsu and Gazdar, 2006; Sordella et al., 2004).
Our ability to generate crystals of the EGFR kinase do-
main in an inactive Src/CDK-like conformation by intro-
ducing a single mutation in the C-lobe of the kinase, lo-
cated far from the active site, provides strong support
for the concept that the active conformation previously
seen in crystals of the EGFR kinase domain is a conse-
quence of mimicry by the crystal of an intrinsic activation
mechanism that moves the kinase domain away from
the otherwise stable inactive Src/Cdk-like conformation.
Mutations in Full-Length EGFR Show that the CDK/
Cyclin-like Asymmetric Dimer Interface Is Required
for Activation of the Receptor
We mutated several residues that are located at the CDK/
cyclin-like dimer interface and tested the effects of these
mutations on autophosphorylation of full-length EGFR in
the cell-based assay. These mutations include P675G,
L680A, L680N, I682Q, and L736R, which involve residues
contributed to the interface by monomer A (the activated
kinase), and I917R, M921R, V924R, and M928R, involving
residues that are contributed to the interface by monomer
B (the cyclin-like partner). All of these mutations, except
L680A, almost completely abrogate the ability of EGFR
to phosphorylate all three of the tested autophosphoryla-
tion sites, either before or after EGF stimulation (Figure 6A).
L680A displays modestly decreased levels of phosphory-
lation compared to the wild-type EGFR. Replacement of
Leu680 by alanine removes the inhibitory wedge between
helix aC and b5, which is expected to activate the kinase.
On the other hand, themutation is also predicted to desta-
bilize the asymmetric dimer interface in the active com-
plex. The observed result for this mutation is likely to
be a combination of these two effects. Replacement of
Leu680 by asparagine completely shuts down the kinaseCell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc. 1143
Figure 6. The Asymmetric Dimer Interface Is Important for EGFR Activation
(A) Single mutations at the asymmetric dimer interface abolish EGFR phosphorylation. Stars and circles denote mutations in the N-lobe and C-lobe
face of the dimer interface, respectively.
(B) Predicted outcomes of a variety of transfection/cotransfection experiments based on the model. Red, orange, and yellow stars denote mutations
in the catalytic site, N-lobe face, and C-lobe face of the dimer interface, respectively. Different combinations are numbered 1 through 10.
(C) Results of the transfection/cotransfection experiments. Combination numbers under the transfection experiments correspond to those in (B).
(D) Effect of mutations in the asymmetric dimer interface on the catalytic activity of the kinase domain in solution and attached to lipid vesicles. DOGS-
NTA-Ni content of vesicles is 5 mole percent. Fold-increase of the catalytic activity upon attachment to vesicles for each protein is indicated on top of
the blue bars. Error bars represent standard error of the linear fitting (see Experimental Procedures).(Figure 6A), presumably because asparagine is less well
accommodated at the hydrophobic CDK/cyclin-like inter-
face than alanine.1144 Cell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc.In order to further test the model and also rule out that
the observed lack of activation of mutant receptors is
due to misfolding or other problems, we determined the
Figure 7. A General Model for the Activation of Members of the EGFR Family
(A) Sequence alignment of the EGFR family members from human andmouse. Two regions containing residues involved in the N- and C-lobe faces of
the dimer interface are shown in the upper and lower panels, respectively. Identical residues are colored in red. Residues in the N- and C-lobe faces of
the dimer interface are denoted by ovals and triangles, respectively. Magenta and cyan highlight residues in the dimer interface that are conserved
among EGFR, ErbB2, and ErbB4 but not in ErbB3.
(B) A general model of the activation mechanism for the EGFR family receptor tyrosine kinases. All the members in the family can act as the cyclin-like
activator for the kinase-active members (EGFR, ErbB2, and ErbB4) after ligand-induced homo- or heterodimerization.ability of onemutant to activate the other in trans. Since the
dimer interface is asymmetric, the model predicts that an
EGFRmoleculewith amutation in theC-lobe face of the di-
mer interface (i.e., with the cyclin-like face disrupted) can
be activated by another EGFR molecule that has an intact
C-lobe interface. Conversely, an EGFR molecule with
a mutation in the N-lobe face of the dimer interface (i.e.,
one that is predicted to be resistant to activation) can act
as a cyclin-like activator for another EGFR molecule in
which the N-lobe face is intact. In order to test these pre-
dictions we constructed a catalytically dead variant of
EGFR inwhich Asp813 (the catalytic base in the kinase do-
main) is replaced by asparagine (EGFRkinase-dead). Trans-
fection of cells with EGFRkinase-dead shows that it does
not undergo autophosphorylation either before or after
EGF stimulation (Figure 6C).
Cotransfection of EGFRkinase-dead with EGFR(I682Q) (an
N-lobe mutant) does not result in detectable levels of au-
tophosphorylation (Figure 6C, combination [3]). In con-trast, cotransfection of EGFRkinase-dead with EGFR(V924R)
results in robust levels of autophosphorylation (Figure 6C,
combination [4]). In this case the catalytically active
EGFR(V924R) (a C-lobe mutant) has an intact N-lobe
face, and although it cannot stimulate itself because of
its disrupted C-lobe face, it can be stimulated by the intact
C-lobe of EGFRkinase-dead (Figure 6B, combination [4]). We
also generated a double mutant, EGFRkinase-dead(I682Q),
which rescues the autophosphorylation of EGFR(V924R)
because it has an intact C-lobe that can interact with the
intact N-lobe of EGFR(V924R) (Figures 6B and 6C, combi-
nation [10]).
Also consistent with the model is the inability of
EGFRkinase-dead(I682Q) to rescue autophosphorylation of
EGFR(I682Q) (Figure 6C, combination [9]). In this case,
both transfected EGFR molecules have defective N-lobe
faces (Figures 6B and 6C, combination [9]). Likewise,
a double mutant EGFRkinase-dead(V924R) (defective C-
lobe face) failed to rescue the autophosphorylation ofCell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc. 1145
either EGFR(I682Q) or EGFR(V924R) (Figures 6B and 6C,
combination [6] and [7]). Additional experiments, including
mutation of Tyr845 in the activation loop, are presented in
Supplemental Data.
The CDK/Cyclin-like Interface Is Required for the
Concentration-Dependent Activation of the EGFR
Kinase Domain
Pro675 is within the extended N-terminal extension of the
kinase domain and makes a hydrophobic contact with
Val956 at the asymmetric dimer interface (Figure 4B). A ki-
nase domain variant containing a P675G mutation pos-
sesses basal kinase activity comparable to that of the
wild-type kinase domain in solution and is only activated
3- to 4-fold when localized to vesicles (Figure 6D). An-
other variant of the kinase domain with a deletion around
Pro675 (D672–677) also shows similar behavior, with
roughly wild-type levels of basal activity but only 3-fold
stimulation upon binding to vesicles.
We also tested two variants of the EGFR kinase domain
that contain the I682Q and V924Rmutations in the vesicle-
linked assay. These two mutant kinase domains show
basal levels of activity comparable to that of the wild-
type (Figure 6D). Upon linking to vesicles, I682Q and
V924R show virtually no increase in their catalytic activi-
ties (1.2- and 1.5-fold increase for I682Q and V924R,
respectively) (Figure 6D).
We determined the catalytic activity of an equimolar
mixture of these twomutant forms of the EGFR kinase do-
main in the absence and presence of lipid vesicles. The re-
sults show that the basal activity of this mixture of the two
mutants is very similar to that of the individual mutants and
to that of the wild-type kinase domain. The activity is stim-
ulated 6-fold when the proteins are linked to vesicles
(Figure 6D), suggesting that V924R (defective C-lobe) is
activated by I682Q (defectiveN-lobe) through heterodime-
rization on the surface of vesicles. In this case only half of
the kinase molecules (i.e., V924R) can be activated, which
explains why the level of stimulation is not as high as that
seen for the wild-type kinase upon attachment to vesicles.
It hasbeenshownthatamutantofEGFRwitha truncated
intracellular region exerts a dominant-negative effect on
cotransfectedwild-type EGFR (Kashles et al., 1991),which
suggests that dimerization of the intracellular region is re-
quired for the activation of EGFR. More evidence support-
ing our model includes a study showing that a catalytically
dead mutant of EGFR (K721M) heterodimerizes with and
activates ErbB2, which lacks a physiological ligand, in an
EGF-dependent manner (Deb et al., 2001).
Conclusions
The model presented here, in which one EGFR kinase do-
main in a dimer acts as a cyclin-like activator for the other,
provides a precise molecular basis for the autoinhibition
and EGF-induced acquisition of catalytic activity by
EGFR. The elegant and simple model for EGFR activation
proposed by Schlessinger (reviewed in Schlessinger,
2002) contains as its central feature the direct communi-1146 Cell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc.cation of the arrival of an external signal to the interior of
the cell by the conversion of a monomeric receptor to a
ligand-induced dimer. The activation of EGFR has such
serious consequences for the cell that nature has clearly
evolved secondary levels of control that minimize inappro-
priate activation of the receptor through intermolecular
collisions. The dimerization interface of the extracellular
domains is kept hidden until unmasked by EGF (Burgess
et al., 2003). In this paper we show that the kinase domain
of EGFR is itself responsive to the dimerization of the re-
ceptors, converting from an inactive Src/CDK-like confor-
mation to an active one in response to an increase in the
local concentration of the receptor. The fundamental on/
off switch utilized by EGFR at the level of the kinase do-
main is the same as that used by the CDK/cyclin com-
plexes, except that EGFR and its relatives serve as their
own ‘‘cyclins.’’
The acquisition of allosteric mechanisms in protein sys-
tems appears to evolve opportunistically, with a funda-
mental function modulated in different ways as a conse-
quence of random mutation and selection. In the case of
receptor tyrosine kinases it is the monomer-dimer equilib-
rium that is likely to be fundamental (Schlessinger, 2002),
with the cyclin-like activation of EGFR being a specialized
variation that may not be utilized by other receptors.
Within the EGFR family, however, the pairwise ability of
the kinase domains to act as activators as well as trans-
ducers for each other clearly leads to a powerful combina-
torial response to a diversity of ligands.
EXPERIMENTAL PROCEDURES
Expression and Purification of the Kinase Domain
DNA encoding residues 672–998 of human EGFR was cloned into
pFAST BAC HT (Invitrogen) using the NcoI and HindIII restriction sites.
The construct contains anN-terminal 6-His tag, a linker, and a cleavage
site for the Tobacco Etch Virus protease(TEV) (MSYYHHHHHHDY
DIPTTENLYFQGAM). All mutations were introduced using the Quik-
change site-directed mutagenesis kit (Stratagene). Sequences of all
the plasmids were confirmed by DNA sequencing.
Recombinant bacmid (Bac-to-Bac expression system, Gibco BRL)
were transfected into Sf9 cells to produce recombinant baculovirus,
which were used to infect Sf9 cells grown in suspension. Cells were
harvested 2–3 days after infection by centrifugation at 4000 3 g and
resuspended in a buffer containing 50 mM Tris, 5% glycerol, 1 mM
DTT, and protease inhibitor cocktail (Roche), pH 8.0. Cells were ho-
mogenized by french press in resuspension buffer and the lysate
was centrifuged at 40000 3 g for 45 min. The supernatant was loaded
onto a 60ml Q-Sepharose Fastflow column (Amersham) equilibrated in
buffer A (50 mM Tris, 5% glycerol, and 15 mM b-mercaptolethanol, pH
8.0). Proteins were eluted using buffer A plus 1MNaCl and loaded onto
a 1 ml Histrap column (Amersham) pre-equilibrated with buffer B (20
mM Tris, 500 mM NaCl, 5% glycerol, 20 mM imidazole, pH 8.0). Pro-
teins were eluted using a gradient of imidazole (20–250 mM) after ex-
tensive wash with buffer B. The proteins were either purified immedi-
ately using a 6 ml Uno-Q column (Bio-rad) to produce His-tagged
kinase domains, or treated with the TEV protease overnight at 4ºC to
remove the N-terminal His-tag before being subjected to Uno-Q
purification for crystallization, analytical ultracentrifugation, and static
light scattering.
Proteins were diluted 10-fold using buffer C (20 mM Tris, 20 mM
NaCl, 5% Glycerol, and 2 mM DTT, pH 8.0) and loaded onto the
Uno-Q column pre-equilibrated with buffer C. Proteins were eluted us-
ing a gradient of NaCl (20–500 mM). Fractions containing the EGFR
protein were pooled, concentrated, and buffer exchanged into 20
mM Tris, 50 mM NaCl, 2 mM DTT, and 2 mM TCEP, pH 8.0. Proteins
were concentrated to 10–30 mg/ml and flash-frozen in liquid nitrogen
and stored at 80ºC. Mass spectrometric analysis was used to con-
firm the identity of the proteins (mass spectrum of the Y845F mutant
is shown in Figure S6).
Preparation of Small Unilamellar Vesicles
DOPC and DOGS-NTA-Ni lipids in chloroform (Avanti Polar Lipids, Inc)
were mixed in a glass tube. A lipid film was formed upon removing
chloroform under a stream of argon gas, followed by putting the
tube under vacuum for at least 3 hr. Rehydration buffer (10 mM
MgCl2, 20 mM Tris, pH 7.5) was added to the lipid film and incubated
for at least 3 hr. Intermittent vigorous vortexing during the incubation
was applied to convert the lipid film into large, multilamellar vesicles.
These mutilamellar vesicles were then forced through a polycarbonate
filter (pore size: 100 nm) 21–41 times using a mini-extruder (Avanti
Polar Lipids, Inc) to yield homogenous small unilamellar vesicles. The
diameter of the vesicles was measured to range from 100–200 nm
by static light scattering (Figure S2).
Kinase Assay in Solution and with Vesicles
A continuous enzyme-coupled kinase assay was performed to mea-
sure the kinase activity of the proteins as described (Barker et al.,
1995), with minor modifications. The ATP concentration was kept at
0.5 mM in all the assays. The buffer used contains 10 mM MgCl2, 20
mMTris, pH 7.5 (replacement of MgCl2 byMnCl2 in the assays resulted
in a substantial increase of the catalytic activity of the kinase domain, as
noted previously; Mohammadi et al., 1993; Wedegaertner and Gill,
1989). The substrate peptide was derived from the region spanning
Y1173 in EGFR (TAENAEYLRVAPQ). All the proteins used in this assay
contain the N-terminal (His)6 tag unless otherwise noted. The protein
concentrations of the EGFR kinase domain used in the assay range
from 3.5 to 14 mM. The total concentration of the DOGS-NTA-Ni in
the bulk solution was kept at 12.5 mM in all the assays with DOG-
NTA-Ni-containing vesicles. For assays of the kinase domain attached
to vesicles, the protein and vesicles were preincubated at 4ºC
for 5 min.
The wild-type EGFR kinase domain was mixed with vesicles con-
taining 0, 0.5, 1, 2, and 5 mole percent of DOGS-NTA-Ni prior to the
start of the assay. The final concentration of the protein in the assay
was 3.5 mM. The substrate peptide concentration used in these assays
was 1 mM. A sample of the kinase domain in the absence of lipid ves-
icles was also assayed using the same setup as a control.
For comparing the specific activity of the wild-type and various mu-
tant forms of the EGFR kinase domain in the presence and absence of
lipid vesicles, the density of DOGS-NTA-Ni on lipid vesicles was kept
at 5mole percent. Preliminary experiments using the substrate peptide
at various concentrations showed that the value of KM for the wild-type
kinase domain and this substrate peptide was greater than 4 mM. Due
to this high value of KM, the values of KM and kcat were not measured
directly. Instead, the value of kcat/KMwas derived from a linear fit to the
data obtained, using concentrations of the peptide that aremuch lower
than the estimated value of KM (V = [S]Vmax/(KM + [S]), Vz (Vmax/KM)[S]
when [S] << KM, kcat = Vmax/amount of the enzyme, where V and Vmax
are the initial velocity and maximum initial velocity, respectively). A de-
tailed description of reaction conditions is given in Table S2.
Crystallization and Structure Determination
The two ATP analog-peptide conjugates used for cocrystallization with
the kinase domain were synthesized as described (Parang et al., 2001).
The peptide sequences are AEEEIYGEFEAKK (the Src substrate pep-
tide; Levinson et al., 2006) and ENAEYLRVAPQK (from a region that
spans Tyr1173 in EGFR). The wild-type kinase domain with the His-
tag removed (containing an N-terminal tri-peptide with sequence‘‘GAM’’ from the vector and residues 682–998 from EGFR) at 6 mg/
ml was used for the crystallization trials. The V924R mutant in complex
with AMP-PNP was crystallized at 8 mg/ml. Crystallization conditions
and structural refinement statistics are summarized in Table S3.
Mammalian Cell-Based Signaling Analysis
The EGFR full-length gene with a fragment encoding an N-terminal
FLAG antibody recognition sequence (DYKDDDDK) inserted between
the 24-residue signal peptide and the mature protein was amplified
by PCR and cloned into the pcDNA3.1 vector (BD Biosciences) using
XhoI and XbaI restriction enzymes. Mutations were generated by using
theQuikchange site-directedmutagenesis kit. All the plasmids used for
transfectionwerepreparedusing theHiSpeedPlasmidMidi kit (Qiagen)
and the sequences were confirmed by DNA sequencing before use.
NIH3T3 cells (which express low levels of endogenous EGFR that
are undetectable by Western blot; Bishayee et al., 1999) were cultured
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum, streptomycin/penicillin, sodium pyruvate, and nones-
sential amino acids (all from Gibco) at 37ºC with 5% CO2. Cells were
plated and cultured overnight in 6-well plates in the same medium
without antibiotics for transfection. Cells were transfected using
Fugene 6 (Roche) according to the manufacturer’s instructions with
a DNA:Fugene 6 ratio of 1.5 mg:4.5 ml when cells reached 50% con-
fluency. Cells were cultured for 36 hr after transfection and serum-
starved for 12 hr before ligand stimulation and harvesting. Ligand
stimulation of cells was performed using 50 ng/ml EGF (PeproTech,
Inc) at 37ºC for 5 min. Cells were lysed in a buffer containing 50 mM
Tris, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 1% Triton
X-100, and a protease inhibitor cocktail (Roche), pH 7.5. The lysates
were centrifuged at 140003 g for 10 min to remove insoluble material.
The supernatants were collected and the protein concentrations were
determined using the Bradford protein assay (Bio-Rad) for normalizing
the total amount of proteins loaded onto the gels. Samples were run on
SDS gels and subjected to Western blot analysis. The total amount of
EGFR was monitored using an anti-FLAG antibody (Sigma). The levels
of phosphorylation of EGFR at three sites were monitored using anti-
EGFR antibodies specific for phosphorylation at Tyr1045 (Cell Signal-
ing), Tyr1068 (Cell signaling), and Tyr1173 (Santa Cruz) (See Supple-
mental Data for details).
Supplemental Data
Supplemental Data include six figures, three tables, and supplemental
text and can be found with this article online at http://www.cell.com/
cgi/content/full/125/6/1137/DC1/.
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